Summary of Workshop

Clinical and Treatment
  • Manfred J. Kist

Abstract

Duodenal and gastric ulcers, when associated with H. pylori infection, are most efficially treated by eradication of the causative agent6. Ulcers refractory to antisecretory drugs can also be healed by this strategy6 and ulcer reccurrences and ulcer complications are virtually prevented2. The antimicrobial therapy is cost effective, when compared with long-term antisecretory treatment, and, especially in childhood it may be preventive against final development of gastric adenocarcinoma and MALT lymphoma3,4. A triple therapy using two antibiotics (mostly a macrolide and an imidazole) in combination with a proton pump inhibitor or a bismuth salt, currently seems to be the most promising eradication treatment with success rates between 70 and 90 percent1,5,6.

Keywords

Pylorus Infection Triple Therapy Gastric Adenocarcinoma Final Development Malt Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Goddard A, Logan R (1995), Eur. J. Gastroenterol. Hepatol 7, 1–3.PubMedGoogle Scholar
  2. 2.
    Labenz J, Börsch G (1994), Digestion 55, 19–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Logan RPH (1994), Lancet 344, 1078–1079.PubMedCrossRefGoogle Scholar
  4. 4.
    Powell KU, Bell GD, Bolton GH et al. (1994), Q. J. Med. 87, 283–290.PubMedGoogle Scholar
  5. 5.
    Treiber G, Walker S, Klotz U (1994), Clin. Pharmacol. Ther. 1994, 55, 486–491.PubMedCrossRefGoogle Scholar
  6. 6.
    Tytgat GNJ 6 (1994), Aliment. Pharmacol. Ther. 8, 359–368.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Manfred J. Kist
    • 1
  1. 1.Institut f. Medizinische Mikrobiologie und HygieneFreiburgGermany

Personalised recommendations